Document Detail


Should we treat all patients with coronary heart disease or the equivalent with statins?
MedLine Citation:
PMID:  19080725     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Statins have proven benefit in preventing cardiovascular events and should be prescribed for almost all patients with coronary heart disease (CHD) or equivalent. However, evidence is lacking to support treating all such individuals. Potential exceptions include those in the initial days of acute coronary syndrome, those with symptomatic systolic heart failure, those with very low low-density lipoprotein cholesterol, diabetic patients without associated metabolic syndrome, and those with high CHD risk calculated mainly on the basis of advanced age. In these cases, the decision to prescribe statins depends on clinical judgment, and surrogate tests for CHD may be useful.
Authors:
Peter Baginsky
Related Documents :
9625405 - Effective lipid modification by partial ileal bypass reduced long-term coronary heart d...
8651835 - Beyond low-density lipoprotein cholesterol. a perspective on low high-density lipoprote...
1806545 - Lipoprotein immune complexes as markers of atherosclerosis.
8901665 - Predominance of dense low-density lipoprotein particles predicts angiographic benefit o...
9389145 - Comparative study on the mechanism of formation of pulse manifestations in coronary hea...
24026945 - The evaluation of mitral valve stenosis: comparison of transthoracic echocardiography a...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current atherosclerosis reports     Volume:  11     ISSN:  1534-6242     ISO Abbreviation:  Curr Atheroscler Rep     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2008-12-16     Completed Date:  2009-03-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897685     Medline TA:  Curr Atheroscler Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  28-35     Citation Subset:  IM    
Affiliation:
College of Osteopathic Medicine, Touro University, Vallejo, CA 94592, USA. pbaginsk@touro.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cholesterol, LDL / blood
Coronary Disease / drug therapy*
Decision Making
Diabetes Complications
Diabetes Mellitus / drug therapy
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / contraindications,  therapeutic use*
Metabolic Syndrome X / drug therapy
Risk Assessment
Chemical
Reg. No./Substance:
0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The effects of statins and sitosterols: benefit or not?
Next Document:  Should we treat all primary prevention patients with statins?